The following is excerpt from the article by Dr. Jerry Avorn published today in the New England Journal The Journal played a centralrole in two prominent drug-safe-ty developments of the 21st cen-tury, involving the cyclooxygen-ase-2 inhibitor rofecoxib (Vioxx)and the oral hypoglycemic agentrosiglitazone (Avandia). Accord- stroke (2005a). Accumulating evi-dence clarified that the VIGORfindings on myocardial infarctionwere […]
